CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 105,758	$ 25,218
Short-term investments	440,629	708,737
Accounts receivable	11,532	22,492
Inventory	19,057	15,801
Other current assets	22,507	23,333
Total current assets	599,483	795,581
Long-term investments	0	64,828
Property, plant and equipment, net	36,803	60,510
Operating lease right-of-use assets	65,896	117,025
Goodwill	76,501	76,501
Other assets	2,323	2,744
Total assets	781,006	1,117,189
Current liabilities:
Accounts payable	5,329	9,747
Accrued compensation	24,392	15,735
Accrued clinical trial expenses	20,461	26,809
Other accrued expenses	15,299	15,468
Operating lease liabilities, current portion	18,508	17,441
Total current liabilities	83,989	85,200
Operating lease liabilities, less current portion	116,145	125,736
Development derivative liability	0	27,726
Liabilities related to the sales of future royalties, net	165,595	195,427
Other long-term liabilities	3,054	3,592
Total liabilities	368,783	437,681
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2022 or December 31, 2021, respectively	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 187,954 shares and 185,468 shares outstanding at September 30, 2022 and December 31, 2021, respectively	19	19
Capital in excess of par value	3,561,878	3,516,641
Accumulated other comprehensive loss	(8,169)	(4,157)
Accumulated deficit	(3,141,505)	(2,832,995)
Total stockholders’ equity	412,223	679,508
Total liabilities and stockholders’ equity	$ 781,006	$ 1,117,189